Search Results for "Diabetes"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Diabetes. Results 361 to 370 of 385 total matches.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014 (Issue 1454)
(TIA). It is not recommended for use in patients
≥75 years old unless they are at high risk (diabetes ...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
or cardiovascular diseases, moderate or severe
immune compromise, diabetes, neurologic or
neuromuscular conditions ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Clopidogrel (Plavix) Revisited
The Medical Letter on Drugs and Therapeutics • Apr 10, 2006 (Issue 1232)
with
aspirin alone in patients with multiple atherothrombotic
risk factors (diabetes, hypertension, etc ...
Clopidogrel (Plavix - Sanofi-Aventis and Bristol-Myers Squibb), an oral thienopyridine that inhibits platelet aggregation, is now being advertised directly to the public on television. Clopidogrel is approved by the FDA for secondary prevention of myocardial infarction (MI), stroke and other vascular events and for use in patients with acute coronary syndrome (unstable angina or non-ST-elevation MI), including those undergoing angioplasty. It is used off-label for patients with ST-elevation acute MI
Rasagiline (Azilect) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
) for Diabetes
Telbivudine (Tyzeka) for Hepatitis B
Coming Soon in Treatment Guidelines:
Common Eye Disorders ...
Rasagiline (Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.
Drugs for Assisted Reproduction
Treatment Guidelines from The Medical Letter • Oct 01, 2003 (Issue 14)
, and
others), a biguanide marketed for oral treatment of type
2 diabetes, has been shown in clinical trials ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
Extrapyramidal QTc Interval Elevated
Drug Diabetes Weight Gain Symptoms Prolongation Prolactin
Aripiprazole ...
The FDA has approved cariprazine (Vraylar – Actavis), an
oral, once-daily, second-generation antipsychotic, for treatment
of schizophrenia and for acute treatment of manic or
mixed episodes associated with bipolar I disorder.
Intravenous Immunoglobulin (IVIG)
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
in The Medical Letter:
Oral Oxymorphone (Opana) for Pain
Sitagliptin (Januvia) for Diabetes
Telbivudine ...
Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019 (Issue 1570)
in patients with cardiovascular
disease, hypertension, diabetes, hyperthyroidism,
closed-angle glaucoma ...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
.
13. B Biondi and AR Cappola. Subclinical hypothyroidism in older
individuals. Lancet Diabetes ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
, elevated
total cholesterol, low HDL cholesterol, elevated systolic
blood pressure, diabetes, current ...
Lasmiditan (Reyvow – Lilly), an oral serotonin
(5-HT1F) receptor agonist, and ubrogepant (Ubrelvy –
Allergan), an oral calcitonin gene-related peptide
(CGRP) receptor antagonist, have been approved
by the FDA for acute treatment of migraine with or
without aura in adults.